Lawmakers Push for Permanent Drug Pricing Reform
Employers providing health benefits should monitor H.R. 3493 for potential impacts on coverage costs.
Updated on Oct. 26, 2026 in Healthcare
Live Poll
Should the federal government pass legislation to mandate lower prescription drug prices for Americans?
Former U.S. lawmakers J.D. Hayworth and Joe Cunningham recently highlighted legislative efforts to curb prescription medication costs. The discussion centers on addressing pricing structures that lead nearly half of U.S. adults to skip doses or cut pills due to high out-of-pocket expenses.
Why it matters
High drug costs directly impact the health and productivity of the American workforce, forcing many to forgo necessary treatments. Legislative moves to align domestic pricing with international benchmarks aim to stabilize these costs, though administrative actions like executive orders remain vulnerable to future policy reversals.
Nearly half of U.S. adults report cutting pills or skipping medication doses because of high costs. While the federal government issued an executive order on Most Favored Nation pricing in spring 2025, the total number of affected drug classes remains subject to ongoing legislative debate.
The players
J.D. Hayworth
Former U.S. Representative who is advocating for structural changes to the national prescription drug pricing system.
Joe Cunningham
Former U.S. Representative focusing on bipartisan paths to lower medication costs for American families.
The details
Legislative proposals like H.R. 3493 seek to implement durable pricing reforms by aligning U.S. costs with international levels. This mechanism aims to bypass the volatility of executive orders, which are subject to rescission by subsequent administrations, by creating a formal statutory framework for drug valuation. The shift focuses on long-term price stability rather than temporary administrative directives.
Timeline
In spring 2025, the administration issued an executive order regarding Most Favored Nation drug pricing.
On October 26, 2026, former lawmakers discussed ongoing efforts to reform prescription drug costs.
Market Landscape
These discussions mark a push to move beyond the Most Favored Nation drug pricing policy initiated in spring 2025. Unlike the previous executive order, current efforts aim to establish a permanent legislative precedent for domestic drug cost alignment.
Business operators should monitor H.R. 3493 for potential shifts in employer-sponsored health plan premiums and long-term drug coverage costs. Keep close contact with benefits advisors to understand how statutory pricing reforms could influence health benefit renewals next year.
The takeaway
Legislators are pivoting toward permanent statutory reform to solve persistent drug affordability issues. Operators should track the status of H.R. 3493 to anticipate potential changes in health coverage mandates and related benefit costs.
Further reading
For broader trends in medical cost regulation, see our Healthcare section.
More information
Access the latest Pharmaceutical Reform Alliance policy information to review proposed legislative frameworks.
Live Poll
Should the federal government pass legislation to mandate lower prescription drug prices for Americans?
